Flotetuzumab
Humanized (from mouse) | |
|---|---|
| Target | CD3, CD123 |
| Clinical data | |
| Other names | MGD006 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C2618H4040N704O813S16 |
| Molar mass | 58898.19 g·mol−1 |
Flotetuzumab (
INN;[1] development code MGD006) is a bispecific antibody[2] designed for the treatment of acute myeloid leukemia.[3][4]
This drug is being developed by MacroGenics, Inc.[5]
References
- ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).
- PMID 30280288.
- PMID 29463552..
- S2CID 23901088.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Flotetuzumab, American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |